Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul-Aug;14(4):302-10.
doi: 10.1002/pst.1686. Epub 2015 May 11.

A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial

Nolan A Wages  1 , Paul W Read  2 , Gina R Petroni  1
Affiliations

A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial

Nolan A Wages et al. Pharm Stat. 2015 Jul-Aug.

Abstract

Dose-finding studies that aim to evaluate the safety of single agents are becoming less common, and advances in clinical research have complicated the paradigm of dose finding in oncology. A class of more complex problems, such as targeted agents, combination therapies and stratification of patients by clinical or genetic characteristics, has created the need to adapt early-phase trial design to the specific type of drug being investigated and the corresponding endpoints. In this article, we describe the implementation of an adaptive design based on a continual reassessment method for heterogeneous groups, modified to coincide with the objectives of a Phase I/II trial of stereotactic body radiation therapy in patients with painful osseous metastatic disease. Operating characteristics of the Institutional Review Board approved design are demonstrated under various possible true scenarios via simulation studies.

Keywords: Phase I; Phase I/II; adaptive design; dose-finding; heterogeneity; optimal dose.

PubMed Disclaimer

References

    1. Braun T. The current design of oncology phase I clinical trials: progressing from algorithms to statistical models. Chinese Clinical Oncology. 2014;3:2. - PubMed
    1. Thall PF, Nguyen HQ, Braun T, Qazilbash MH. Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule-Dose Regimes. Biometrics. 2013;69:673–682. - PMC - PubMed
    1. Wages NA, Conaway MR. Phase I/II adaptive design for drug combination oncology trials. Statistics in Medicine. 2014;33:1990–2003. - PMC - PubMed
    1. Zang Y, Lee JJ, Yuan Y. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clinical Trials. 2014;11:319–327. - PMC - PubMed
    1. Ramanathan R, Egorin M, Takimoto C, Remick S, Doroshow J, LoRusso P, et al. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. Journal of Clinical Oncology. 2008;26:563–569. - PubMed

Publication types

MeSH terms

LinkOut - more resources